Sunshine Lake Pharma (HKG:6887) said it has entered into a cooperation framework agreement with Shenzhen XtalPi Technology to pursue a joint venture focused on AI-driven drug research and development, according to a Monday Hong Kong bourse filing.
Shares of the pharmaceutical firm were up over 3% in Tuesday morning trade.
The parties plan to build an AI drug R&D platform, including a joint laboratory for innovative drug discovery, joint development of AI large models across the drug development lifecycle, and the creation of a "Model-as-a-Service" business model, the filing showed.